Animal experiments indicate that CTLA4-Ig has the potential to block unwanted immune responses without compromising the ability to fight off other infections. BMS is testing CTLA4 in humans for ...

Financial writer discusses Coya Therapeutics, Inc.'s Treg therapies for neurodegenerative diseases like ALS, FTD, and PD.

Weight gain and fasting glucose tolerance were not affected. CTLA4-Ig injections reduced the number of T cells in epididymal AT (epiAT) but not the inflammatory cytokines levels and failed to ...

In December, Coya Therapeutics announced that five of eight patients enrolled in the investigator-initiated academic study of LD IL-2 + CTLA4-Ig combination in patients with Frontotemporal ...

The cytotoxic T lymphocyte–associated antigen 4–Ig prolongs allograft survival in several rodent models and in some instances can lead to tolerance induction, but the exact mechanisms involved have ...